JP2024516320A5 - - Google Patents
Info
- Publication number
- JP2024516320A5 JP2024516320A5 JP2023568549A JP2023568549A JP2024516320A5 JP 2024516320 A5 JP2024516320 A5 JP 2024516320A5 JP 2023568549 A JP2023568549 A JP 2023568549A JP 2023568549 A JP2023568549 A JP 2023568549A JP 2024516320 A5 JP2024516320 A5 JP 2024516320A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- amino acid
- seq
- chain shown
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110495363 | 2021-05-07 | ||
| CN202110495363.7 | 2021-05-07 | ||
| CN202210436873 | 2022-04-25 | ||
| CN202210436873.1 | 2022-04-25 | ||
| PCT/CN2022/091187 WO2022233320A1 (zh) | 2021-05-07 | 2022-05-06 | 与Fc受体结合改变的Fc突变体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516320A JP2024516320A (ja) | 2024-04-12 |
| JP2024516320A5 true JP2024516320A5 (https=) | 2025-05-12 |
Family
ID=83932014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568549A Pending JP2024516320A (ja) | 2021-05-07 | 2022-05-06 | Ｆｃ受容体への結合が改変されたＦｃ変異体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240228579A1 (https=) |
| EP (1) | EP4335868A4 (https=) |
| JP (1) | JP2024516320A (https=) |
| CN (1) | CN117295760A (https=) |
| AU (1) | AU2022269145A1 (https=) |
| CA (1) | CA3218187A1 (https=) |
| TW (1) | TWI839729B (https=) |
| WO (1) | WO2022233320A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121712795A (zh) * | 2023-08-30 | 2026-03-20 | 安斯泰来制药株式会社 | Fc区改造体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
| EP2471813B1 (en) * | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| TW201245227A (en) * | 2011-03-29 | 2012-11-16 | Roche Glycart Ag | Antibody Fc variants |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| RU2639287C2 (ru) * | 2012-06-27 | 2017-12-20 | Ф. Хоффманн-Ля Рош Аг | Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения |
| WO2017106684A2 (en) * | 2015-12-17 | 2017-06-22 | Janssen Biotech, Inc. | Antibodies specifically binding hla-dr and their uses |
| WO2018027204A1 (en) * | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| CN113603780B (zh) * | 2017-03-28 | 2022-07-01 | 礼进生物医药科技（上海）有限公司 | 用于增强肿瘤微环境中免疫应答的治疗剂和方法 |
| CN112912395B (zh) * | 2018-08-20 | 2024-08-23 | 辉瑞公司 | 抗gdf15抗体、组合物和使用方法 |
-
2022
- 2022-05-06 CN CN202280033488.0A patent/CN117295760A/zh active Pending
- 2022-05-06 EP EP22798660.1A patent/EP4335868A4/en active Pending
- 2022-05-06 WO PCT/CN2022/091187 patent/WO2022233320A1/zh not_active Ceased
- 2022-05-06 TW TW111117182A patent/TWI839729B/zh active
- 2022-05-06 CA CA3218187A patent/CA3218187A1/en active Pending
- 2022-05-06 AU AU2022269145A patent/AU2022269145A1/en active Pending
- 2022-05-06 JP JP2023568549A patent/JP2024516320A/ja active Pending
- 2022-05-06 US US18/558,655 patent/US20240228579A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3356420B1 (en) | Multispecific antibodies | |
| JP2021007390A5 (https=) | ||
| EP3174897B1 (en) | Multispecific antibodies | |
| ES2534313T3 (es) | Anticuerpos anti-CXCR4 para el tratamiento del VIH | |
| JP2007530435A5 (https=) | ||
| US6270993B1 (en) | VEGF-binding polypeptide | |
| EP3027649B1 (en) | Tnfa-il-17 bispecific antibodies | |
| JP2021533779A5 (https=) | ||
| JP2022504550A5 (https=) | ||
| JP2022512043A5 (https=) | ||
| KR20250152665A (ko) | Ｆc-함유 폴리펩타이드의 안정화 | |
| RU2007129676A (ru) | Антитела к рецептору альфа 1 il-13 и их применение | |
| CA2376485A1 (en) | Recombinant anti-cd40 antibody and uses thereof | |
| JP2023015301A5 (https=) | ||
| FI3830120T3 (fi) | CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini | |
| JP2022534135A5 (https=) | ||
| JP2024521472A5 (https=) | ||
| JP2023530663A5 (https=) | ||
| CN1381461A (zh) | 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用 | |
| CN114127126A (zh) | ETA抗体与TGF-βTrap的融合蛋白质，以及其药物组合物和应用 | |
| IL145676A (en) | Tumor necrosis factor homologs and nucleic acids encoding the same | |
| JP2023171909A5 (https=) | ||
| JPWO2022224997A5 (https=) | ||
| JP2024516320A5 (https=) | ||
| CN117659189A (zh) | Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用 |